Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
J Vet Cardiol ; 53: 72-76, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38735230

ABSTRACT

A nine-year-old spayed female domestic shorthair cat with a previous diagnosis of hypertrophic cardiomyopathy and treated for one month with atenolol (6.25 mg q 12 h) was referred for respiratory distress and anorexia. The cat was diagnosed with pulmonary oedema secondary to obstructive hypertrophic cardiomyopathy. After stabilisation, she was discharged with furosemide (1 mg/kg q 12 h), clopidogrel (18.75 mg q 24 h), atenolol (6.25 mg q 12 h), and mirtazapine (2 mg/cat q 24 h) to increase appetite. At recheck, the cat was lethargic and presented with severe bradycardia with a junctional escape rhythm and ventriculoatrial conduction. The mirtazapine was discontinued due to its possible side-effects on cardiac rhythm. After three days, the atenolol was halved because the bradyarrhythmia was still present. After 10 days, the rhythm returned to sinus; atenolol was reintroduced twice daily with no further side-effects. The absence of a sinus rhythm with a junctional escape rhythm and P' retroconduction is compatible with a third-degree sinus block or a sinus standstill; the differentiation of these rhythm disturbances is impossible, based on the surface electrocardiogram (ECG). The sinus rhythm was restored after mirtazapine was withdrawn. However, it is not possible to rule out the role of the atenolol or the combined effect of the two drugs. The cat was affected by hypertrophic cardiomyopathy, and the role of myocardial remodelling cannot be excluded. This is the first time that a bradyarrhythmia consequent to the treatment with atenolol and mirtazapine was described in a cat.


Subject(s)
Atenolol , Bradycardia , Cardiomyopathy, Hypertrophic , Cat Diseases , Mirtazapine , Female , Mirtazapine/therapeutic use , Animals , Atenolol/therapeutic use , Atenolol/adverse effects , Cats , Cat Diseases/drug therapy , Cardiomyopathy, Hypertrophic/veterinary , Cardiomyopathy, Hypertrophic/drug therapy , Bradycardia/veterinary , Bradycardia/chemically induced , Bradycardia/drug therapy , Mianserin/analogs & derivatives , Mianserin/therapeutic use , Mianserin/adverse effects , Adrenergic beta-1 Receptor Antagonists/therapeutic use , Adrenergic beta-1 Receptor Antagonists/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL